Immune treatment in COVID-19.
Rev Esp Quimioter
; 35 Suppl 1: 59-63, 2022 Apr.
Article
in English
| MEDLINE | ID: covidwho-2309886
ABSTRACT
Current immune treatment directed to avoid viral replication relies mainly in convalescent plasma and monoclonal antibodies (mAbs). No clinical benefit for convalescent plasma has been reported in a meta-analysis and systematic review compared to standard of care. MAbs are recombinant proteins capable to bind with SARS-CoV-2 preventing its entrance into cells. Several mAbs have shown reduction in viral load and/or progression of the disease such as casirivimab-imdevimab, bamlanivimab-etesevimab and sotrovimab. After the apparition of Omicron variant, it has been reported that sotrovimab retained its activity whereas the other two combinations exhibited loss of neutralizing activity. Several aspects as the target population, timing and doses, serological patient status and evolution of variants still require attention, monitorization and further studies for knowledge gaps.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Spike Glycoprotein, Coronavirus
/
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
/
Reviews
/
Systematic review/Meta Analysis
Topics:
Variants
Limits:
Humans
Language:
English
Journal:
Rev Esp Quimioter
Journal subject:
Drug Therapy
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS